Overview

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

Window of Opportunity Trial of Olaparib and Durvalumab (MEDI4736) before Standard Neoadjuvant Chemotherapy for Stage II/III Triple Negative or Low ER+ Breast Cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Seoul National University Hospital

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab
Olaparib